GOV logo

InsuletDB:GOV Stock Report

Market Cap €17.1b
Share Price
€241.00
My Fair Value
€291
17.3% undervalued intrinsic discount
1Y36.7%
7D-2.6%
Portfolio Value
​
View

Insulet Corporation

DB:GOV Stock Report

Market Cap: €17.1b

Insulet (GOV) Stock Overview

Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More details

GOV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 11.29% per year

Earnings grew by 71.9% over the past year

Risk Analysis

GOV passed our risk checks.

GOV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Insulet Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Insulet
Historical stock prices
Current Share PriceUS$243.10
52 Week HighUS$290.90
52 Week LowUS$160.50
Beta1.35
1 Month Change-7.50%
3 Month Change14.08%
1 Year Change36.73%
3 Year Change3.82%
5 Year Change48.69%
Change since IPO2,023.14%

Recent News & Updates

Recent updates

Shareholder Returns

GOVDE Medical EquipmentDE Market
7D-2.6%-0.5%0.4%
1Y36.7%-12.6%18.3%

Return vs Industry: GOV exceeded the German Medical Equipment industry which returned -12.3% over the past year.

Return vs Market: GOV exceeded the German Market which returned 19.3% over the past year.

Price Volatility

Is GOV's price volatile compared to industry and market?
GOV volatility
GOV Average Weekly Movement6.7%
Medical Equipment Industry Average Movement6.4%
Market Average Movement5.1%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.6%

Stable Share Price: GOV has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: GOV's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20003,900Ashley McEvoywww.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.

Insulet Corporation Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
GOV fundamental statistics
Market cap€17.11b
Earnings (TTM)€344.04m
Revenue (TTM)€1.88b
49.2x
P/E Ratio
9.0x
P/S Ratio

Is GOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GOV income statement (TTM)
RevenueUS$2.20b
Cost of RevenueUS$651.00m
Gross ProfitUS$1.55b
Other ExpensesUS$1.15b
EarningsUS$402.20m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 07, 2025

Earnings per share (EPS)5.72
Gross Margin70.39%
Net Profit Margin18.29%
Debt/Equity Ratio127.4%

How did GOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 20:22
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insulet Corporation is covered by 60 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
Jeffrey JohnsonBaird
null nullBaird